In:
The Oncologist, Oxford University Press (OUP), Vol. 15, No. 8 ( 2010-08-01), p. 819-825
Abstract:
After completing this course, the reader will be able to: Evaluate the clinical use of bevacizumab, both for cancer and for non-oncologic diseases, and discuss approved and investigational combination chemotherapies that include bevacizumab.Describe the pharmacology of bevacizumab and its mechanism of action in order to predict degrees of patient response. CME This article is available for continuing medical education credit at CME.TheOncologist.com.
Type of Medium:
Online Resource
ISSN:
1083-7159
,
1549-490X
DOI:
10.1634/theoncologist.2009-0317
Language:
English
Publisher:
Oxford University Press (OUP)
Publication Date:
2010
detail.hit.zdb_id:
2023829-0
Permalink